"label","uuid:ID","description","id","name","instanceType","text"
"","47a3614d-5a60-44ad-95eb-c2463adc7f2b","Main objective","Objective_1","OBJ1","Objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."
"","a70a8a5c-68c7-4b48-b2f4-a25bb3b78e1d","Safety","Objective_2","OBJ2","Objective","To document the safety profile of the xanomeline TTS."
"","ffeabc48-408e-49ab-a808-4376fd175475","Behaviour","Objective_3","OBJ3","Objective","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas."
"","a8828450-9641-49a9-a982-f29683a15f61","","Objective_4","OBJ4","Objective","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5)."
"","bd62b234-cdf9-4fc9-bd28-2002dbecb27e","","Objective_5","OBJ5","Objective","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2)."
"","6a7c73be-0c9a-4b56-9a1b-52e7a7e1c91f","","Objective_6","OBJ6","Objective","To assess the treatment response as a function of Apo E genotype."
